Benitec BiopharmaBNTC -5.01%34 Quick Ratio is 56.82 as of Mar. 2026, which is 455% above its 10-year median of 10.23. GuruFocus rates BNTC with a GF Score™ of 34/100. Among 1,417 Biotechnology companies, Benitec Biopharma ranks better than 98.87% on this metric.
Benitec Biopharma has a quick ratio of 56.82. It generally indicates good short-term financial strength.
The historical rank and industry rank for Benitec Biopharma's Quick Ratio or its related term are showing as below:
BNTC'
s Quick Ratio Range Over the Past 10 Years
Min: 0.94 Med: 10.23 Max: 67.69
Current: 56.82
During the past 12 years, Benitec Biopharma's highest Quick Ratio was 67.69. The lowest was 0.94. And the median was 10.23.
BNTC's Quick Ratio is ranked better than 98.87% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs BNTC: 56.82
Benitec Biopharma (NAS:BNTC) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Benitec Biopharma Quick Ratio Related Terms
Benitec Biopharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Benitec Biopharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Benitec Biopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Benitec Biopharma's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma (BNTC) has a Quick Ratio of 56.82 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Benitec Biopharma and its competitors. This is 455% above median its historical median of 10.23. Over the past decade, Benitec Biopharma's Quick Ratio has ranged from 0.94 to 67.69. According to the industry distribution chart, Benitec Biopharma ranks #16 out of 1417 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Benitec Biopharma's Quick Ratio too high?
Benitec Biopharma's current Quick Ratio of 56.82 is 455% above median its 10-year median of 10.23. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 67.69. The Biotechnology industry median Quick Ratio is 3.60. Benitec Biopharma's value of 56.82 is 1478.3% above this industry median. Based on the distribution chart, Benitec Biopharma ranks #16 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's Quick Ratio compare to OABI and FBRX?
According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #16 out of 1417 companies for Quick Ratio. This places Benitec Biopharma in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Benitec Biopharma's value of 56.82 is 1478.3% above this benchmark. Historically, Benitec Biopharma's own Quick Ratio has ranged from 0.94 to 67.69 over the past decade. While the company's 10-year median is 10.23 vs. the industry median of 3.60, Benitec Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Benitec Biopharma's current Quick Ratio of 56.82 is 1478.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Benitec Biopharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Benitec Biopharma's current Quick Ratio is 56.82, which is 455% above median its own 10-year median of 10.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current Quick Ratio of 56.82. The current Quick Ratio is 56.82, which is 455% above median its 10-year median of 10.23 and 1478.3% above the Biotechnology industry median of 3.60. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current Quick Ratio is 56.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score
Get the complete analysis for BNTC
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTC has been successfully added to your 
